IL153814A0 - Drug delivery system for poorly water soluble drugs - Google Patents

Drug delivery system for poorly water soluble drugs

Info

Publication number
IL153814A0
IL153814A0 IL15381401A IL15381401A IL153814A0 IL 153814 A0 IL153814 A0 IL 153814A0 IL 15381401 A IL15381401 A IL 15381401A IL 15381401 A IL15381401 A IL 15381401A IL 153814 A0 IL153814 A0 IL 153814A0
Authority
IL
Israel
Prior art keywords
water soluble
poorly water
soluble drugs
delivery system
drug delivery
Prior art date
Application number
IL15381401A
Original Assignee
Kemestrie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemestrie Inc filed Critical Kemestrie Inc
Publication of IL153814A0 publication Critical patent/IL153814A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Colloid Chemistry (AREA)

Abstract

The present invention relates to a method for modifying the solubilization rates of poorly water soluble drugs, using a chitosan-xanthan hydrogel. In addition, the present invention relates to a process for the preparation of chitosan-xanthane hydrogels as well as for the preparation of hydrogels comprising a poorly water soluble drug.
IL15381401A 2000-07-07 2001-07-06 Drug delivery system for poorly water soluble drugs IL153814A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21662700P 2000-07-07 2000-07-07
US25238900P 2000-11-21 2000-11-21
PCT/CA2001/000993 WO2002003962A2 (en) 2000-07-07 2001-07-06 Drug delivery system for poorly water soluble drugs

Publications (1)

Publication Number Publication Date
IL153814A0 true IL153814A0 (en) 2003-07-31

Family

ID=26911183

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15381401A IL153814A0 (en) 2000-07-07 2001-07-06 Drug delivery system for poorly water soluble drugs

Country Status (12)

Country Link
US (1) US20030157171A1 (en)
EP (1) EP1299089B1 (en)
JP (1) JP2004502722A (en)
AT (1) ATE322891T1 (en)
AU (1) AU2001272262A1 (en)
BR (1) BR0112258A (en)
CA (1) CA2415081A1 (en)
DE (1) DE60118742D1 (en)
IL (1) IL153814A0 (en)
NO (1) NO20030073L (en)
NZ (1) NZ523418A (en)
WO (1) WO2002003962A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005062041A1 (en) * 2003-12-24 2005-07-07 Astrazeneca Ab Pharmaceutical dissolution testing using a non-ionic surfactant
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
EP1868587A2 (en) * 2005-04-08 2007-12-26 Abbott Laboratories Pharmaceutical formulations comprising fenofibric acid and/or its salts
AU2006296991A1 (en) * 2005-09-28 2007-04-05 Dnp Canada Inc. Combination of polychitosamine and fibrate for the prevention and treatment of hyperlipidemia
EP1942872A2 (en) * 2005-11-04 2008-07-16 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
WO2007117590A2 (en) 2006-04-05 2007-10-18 Woodland Biofuels Inc. System and method for converting biomass to ethanol via syngas
US20100129423A1 (en) * 2007-04-19 2010-05-27 Medovent Gmbh Device made at least partially of n-acetylchitosan with controlled biodissolution
CA2810842C (en) * 2010-09-09 2018-06-26 Micell Technologies, Inc. Macrolide dosage forms
WO2013018050A2 (en) 2011-08-01 2013-02-07 Ranbaxy Laboratories Limited Dissolution enhanced controlled drug delivery system for poorly water soluble drugs
CN103315960A (en) * 2012-03-19 2013-09-25 胡容峰 Solid self-microemulsion based on spherical crystallization technique and preparation method thereof
US20200262937A1 (en) * 2017-09-27 2020-08-20 Association For The Advancement Of Tissue Engineering Cell Based Technologies & Therapies (A4Tec)- High molecular weight chitosan, process for obtaining and uses thereof
KR102407470B1 (en) * 2021-08-09 2022-06-10 인제대학교 산학협력단 Method for detecting the amount of drug released on a hydrogel
CN114515268B (en) * 2022-02-21 2024-06-21 上海宣泰医药科技股份有限公司 Ursodeoxycholic acid pharmaceutical composition, preparation method and pharmaceutical preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620706A (en) * 1995-04-10 1997-04-15 Universite De Sherbrooke Polyionic insoluble hydrogels comprising xanthan and chitosan
CA2243619A1 (en) * 1998-07-17 2000-01-17 Universite De Sherbrooke Chitosan- and xanthan-based polyionic hydrogels for the stabilization and controlled release of vitamins

Also Published As

Publication number Publication date
ATE322891T1 (en) 2006-04-15
JP2004502722A (en) 2004-01-29
DE60118742D1 (en) 2006-05-24
BR0112258A (en) 2003-06-24
CA2415081A1 (en) 2002-01-17
NO20030073L (en) 2003-03-06
US20030157171A1 (en) 2003-08-21
WO2002003962A3 (en) 2002-06-13
EP1299089A2 (en) 2003-04-09
AU2001272262A1 (en) 2002-01-21
WO2002003962A2 (en) 2002-01-17
NO20030073D0 (en) 2003-01-07
NZ523418A (en) 2004-09-24
EP1299089B1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
IL153814A0 (en) Drug delivery system for poorly water soluble drugs
AU1729397A (en) Process to prepare soluble delivery systems using volatile salts
SG147286A1 (en) Manufacture of polyglumate-therapeutic agent conjugates
MXPA03007837A (en) Compositions for delivering bisphosphonates.
HK1070063A1 (en) Stable polymorph of flibanserin, technical processfor its preparation and the use thereof for prepa ring medicaments
IL160027A0 (en) Ophthalmic depot formulations for periocular or subconjunctival administration
MX9602683A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances.
MXPA02009275A (en) Method for preparing high pressure high shear dispersions containing physiologically active ingredients.
MXPA03005044A (en) Reversible gelling system for ocular drug delivery.
EP1067911A4 (en) Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
HUP0300163A3 (en) Clathrate complexes formed by hyaluronic acid derivates, process for their preparation and pharmaceutical compositions containing them and their use
HK1040983A1 (en) Quinones for treatment of diseases.
EA200400455A1 (en) METHOD FOR PREPARING A QUICKLY SOLUBLE DOSAGE FORM
ZA200710011B (en) A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein
CA2356959A1 (en) Water-insoluble drug delivery system
TW200517144A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
AU2003256882A1 (en) Methods of drug delivery using sulphated chitinous polymers
PL323496A1 (en) Pharmaceutic composition obtained by adding a taste improving agent to a drug
AU7599900A (en) Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles
SG153663A1 (en) Process for the production of biodegradable, functionalised polymer particles and use thereof as pharmaceutical supports
AU2001250429A1 (en) Method for producing 2-alkyl-3-chlorophenols
AU2356501A (en) Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments
AU2001252825A1 (en) Thieno(2,3-d)pyrimidinediones and their use as pharmaceuticals
AP2003002897A0 (en) Processes and intermediates for preparing benzyl epoxides
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same